Role of atypical antipsychotics in the treatment of generalized anxiety disorder

CNS Drugs

Volumn 28, Issue 6, 2014, Pages 519-533

  Hershenberg, Rachel ^a,b   Gros, Daniel F ^c,d   Brawman Mintzer, Olga ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANXIETY DISORDER; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENERALIZED ANXIETY DISORDER; HUMAN; LONG TERM CARE; MONOTHERAPY; OFF LABEL DRUG USE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; ANXIETY DISORDERS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; LEARNING; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; DIBENZOTHIAZEPINES; GENERALIZATION (PSYCHOLOGY); HUMANS; PIPERAZINES; QUINOLONES; RISPERIDONE; TREATMENT OUTCOME;

EID: 84903816192     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0162-6     Document Type: Review

References (97)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, rev. Washington, DC: American Psychiatric Association; 1987.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
4. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Association: Washington, DC; 2013.
5. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35(12):1747-59. (Pubitemid 41672353)
6. Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med. 2007;146(5):317-25. (Pubitemid 351650592)
7. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-71.
8. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004;351(1):13-22. (Pubitemid 38857243)
9. Milanak ME, Gros DF, Magruder KM, Brawman-Mintzer O, Frueh BC. Prevalence and features of generalized anxiety disorder in Department of Veteran Affairs primary care settings. Psychiatry Res. 2013;209:173-9.
10. Phillips AC, Batty GD, Gale CR, Deary IJ, Osborn D, MacIntyre K, Carroll D. Generalized anxiety disorder, major depressive disorder, and their comorbidity as predictors of all-cause and cardiovascular mortality: the Vietnam experience study. Psychosom Med. 2009;71(4):395-403.
11. Brown TA, Barlow DH, Liebowitz MR. The empirical basis of generalized anxiety disorder. Am J Psychiatry. 1994;151(9):1272-80. (Pubitemid 24281749)
12. Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness - course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. 2003;17(3):173-9. (Pubitemid 36644715)
13. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. Major depression and generalized anxiety disorder: same genes, (partly) different environments? Arch Gen Psychiatry. 1992;49(9):716.
14. Rodríguez BF, Bruce SE, Pagano ME, Keller MB. Relationships among psychosocial functioning, diagnostic comorbidity, and the recurrence of generalized anxiety disorder, panic disorder, and major depression. J Anxiety Disord. 2005;19(7):752-66. (Pubitemid 41074946)
15. Wittchen H-U, Zhao S, Kessler RC, Eaton WW. DSM-III - R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:355-64. (Pubitemid 24176813)
16. Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J, Rosenbaum JF. Anxiety disorders in major depression. Compr Psychiatry. 2000;41(2):97-102. (Pubitemid 30149018)
17. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol. 2000;15(6):319-28.
18. Kessler RC, DuPont RL, Berglund P, Wittchen H-U. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999;156(12):1915-23.
19. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996;2(4):167-72. (Pubitemid 126812824)
20. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry. 1999;60:427-35. (Pubitemid 29369796)
21. Woodman CL, Noyes R, Black DW, Schlosser S, Yagia SJ. A five-year follow-up study of generalized anxiety disorder and panic disorder. J Nerv Men Dis. 1999;187:3-9. (Pubitemid 29063078)
22. Wittchen H-U, Kessler RC, Beesdo K, Krause P, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63:24-34. (Pubitemid 34535254)
23. Dilbaz N, Darcin EA. Treatment of generalized anxiety disorders: unmet needs. In: Durbano F, editor. New insights into anxiety disorders. New York: InTech. ISBN:978-953-51-1053-8. http://www.intechopen.com/books/new-insights- into-anxiety-disorders/treatment-of-generalized-anxiety-disorders-unmet-needs.
24. Newman M, Borkovec T. Cognitive behaviour therapy: a guide for the practising clinician. In: Simos G, editor. Cognitive behavioral therapy for worry and generalized anxiety disorder. New York: Taylor & Francis; 2002. p. 150-72.
25. Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry. 2001;62:37-45. (Pubitemid 32537576)
26. Hayes SC, Villatte M, Levin M, Hildebrandt M. Open, aware, and active: contextual approaches as an emerging trend in the behavioral and cognitive therapies. Annu Rev Clin Psychol. 2011;7:141-68.
27. Orsillo SM, Roemer L, Barlow DH. Integrating acceptance and mindfulness into existing cognitive-behavioral treatment for GAD: a case study. Cognit Behav Pract. 2003;10(3):222-30. (Pubitemid 38281786)
28. Roemer L, Orsillo SM. An open trial of an acceptance-based behavior therapy for generalized anxiety disorder. Behav Ther. 2007;38(1):72-85. (Pubitemid 46209068)
29. Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007;(1):CD001848.
30. Newman MG, Castonguay LG, Borkovec TD, Fisher AJ, Boswell JF, Szkodny LE, Nordberg SS. A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. J Consult Clin Psychol. 2011;79(2):171-81.
31. Wells A, Welford M, King P, Papageorgiou C, Wisely J, Mendel E. A pilot randomized trial of metacognitive therapy vs applied relaxation in the treatment of adults with generalized anxiety disorder. Behav Res Ther. 2010;48(5):429-34.
32. Katzman MA. Current considerations in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(2):103-20.
33. Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2011;12(16):2457-67.
34. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller HJ. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77-84.
35. Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342:1-11.
36. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 2007;21(8):864-72. (Pubitemid 350029180)
37. Katzman MA, Copeland A, Klassen LJ, Chokka P, Brawman-Mintzer O. Pharmacotherapy for generalized anxiety disorder. Psychiatr Ann. 2011;41(2):95-103.
38. Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Human Psychopharmacol Clin Exp. 2010;25(1):17-29.
39. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV: medications and other biological treatments. Can J Psychiatry. 2001;46:38S-58S.
40. Dobrea C, Buoli M, Arici C, Camuri G, Dell'Osso B, Altamura AC. Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. Expert Opin Drug Saf. 2012;11(6):893-9.
41. Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry. 1996;29(04):127-34. (Pubitemid 26247561)
42. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin. 2004;20:1357-63. (Pubitemid 39361338)
43. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001;23(11):1839-54. (Pubitemid 33121972)
44. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004;65:565-8.
45. Denys D, de Geus F, Van Megen HJ, Westenberg HG. A doubleblind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65:1040-8.
46. Doree J-P, Rosiers JD, Lew V, Gendron A, Elie R, Stip E, Valérie Tourjman S. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin. 2007;23(2):333-41. (Pubitemid 46333382)
47. Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003;23(1):15-20. (Pubitemid 36164420)
48. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005;66(6):736-43. (Pubitemid 40942420)
49. Patkar AA, Pae C-U. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27 Suppl 1:S29-37.
50. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 2004;9(10 Suppl 11):6.
51. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(Suppl 5):40-8. (Pubitemid 40934073)
52. Sharpley AL, Vassallo CM, Cowen PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo. Biol Psychiatry. 2000;47(5):468-70. (Pubitemid 30110618)
53. Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacother J Human Pharmacol Drug Ther. 2010;30(9):942-51.
54. Buoli M, Caldiroli A, Caletti E, Paoli RA, Altamura AC. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother. 2013;14(2):175-84.
55. Hoge EA, Worthington JJ, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13:522-7. (Pubitemid 351960777)
56. Worthington III JJ, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005;20(1):9-11. (Pubitemid 40105542)
57. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry. 2005;57(5):474-9. (Pubitemid 40311981)
58. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158(5):765-74. (Pubitemid 32429846)
59. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21(8):600-20.
60. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006;21(6):450-5. (Pubitemid 44069792)
61. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67(3):381-5.
62. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66(10):1321-13235.
63. Pandina GJ, Canuso CM, Turkoz I, Kujawa M, Mahmoud RA. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull. 2007;40(3):41-57.
64. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology. 1999;141(3):267-78. (Pubitemid 29196076)
65. Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159(10):1777-9.
66. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16(4):365-8. (Pubitemid 35470582)
67. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211-5. (Pubitemid 43208966)
68. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther. 2010;32:S3-20.
69. Nelson JC, Pikalov A, Berman RM. Augmentation treatment in major depressive disorder: focus on aripiprazole. Neuropsychiatr Dis Treat. 2008;4(5):937-48.
70. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009;48:1110-9.
71. Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol. 2007;27(2):207-10. (Pubitemid 46594942)
72. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand. 2000;101(6):416-32. (Pubitemid 30365564)
73. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13(2):137-77. (Pubitemid 47052346)
74. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25:301-10. (Pubitemid 41065070)
75. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol. 2005;25(5):497-9. (Pubitemid 41368377)
76. Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010;30(2):185-9.
77. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-60. (Pubitemid 40905587)
78. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev. 2004;(2):CD000967.
79. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2007;33(10):2303-12.
80. Goldstein J, Christoph G, Grimm S, Liu J, Widzowski D, Brecher M. Quetiapine's antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuropsychopharmacol. 2007;17:S401.
81. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22(8):1480-6.
82. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington III JJ, Zhang W, Davidson JR, Pollack MH. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology. 2008;197:675-81.
83. Gabriel A. The extended-release formulation of quetiapine fumarate (quetiapine XR) adjunctive treatment in partially responsive generalized anxiety disorder (GAD): an open label naturalistic study. La Clinica Terapeutica. 2011;162(2):113.
84. Altamura AC, Serati M, Buoli M, Dell'Osso B. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011;26(4):201-5.
85. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010;13:305-20.
86. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11-24.
87. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31(4):418-28.
88. Merideth C, Cutler AJ, She F, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol. 2012;27(1):40-54.
89. Mezhebovsky I, Magi K, She F, Datto C, Eriksson H. Doubleblind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry. 2013;28(6):615-25.
90. Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011;72(8):1063-71.
91. Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. JAMA. 2011;206(12):1359-69.
92. Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61(8):1356-70. (Pubitemid 47052363)
93. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62:3232-40.
94. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-35.
95. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O'Reardon JP, Lovett ML, Gladis MM, Brown LL. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):409-16. (Pubitemid 40471690)
96. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, Gallop R, McGlinchey JB, Markley DK, Gollan JK. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol. 2006;74(4):658.
97. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;12(1):72-86. (Pubitemid 40309355)